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Abstract
Growth factor induced signaling cascades are key regulatory elements in tissue development, maintenance and
regeneration. Perturbations of these cascades have severe consequences, leading to developmental disorders and
neoplastic diseases. As a major function in signal transduction, activating mutations in RAF family kinases are the cause of
human tumorigenesis, where B-RAF V600E has been identified as the prevalent mutant. In order to address the oncogenic
function of B-RAF V600E, we have generated transgenic mice expressing the activated oncogene specifically in lung alveolar
epithelial type II cells. Constitutive expression of B-RAF V600E caused abnormalities in alveolar epithelium formation that led
to airspace enlargements. These lung lesions showed signs of tissue remodeling and were often associated with chronic
inflammation and low incidence of lung tumors. The inflammatory cell infiltration did not precede the formation of the lung
lesions but was rather accompanied with late tumor development. These data support a model where the continuous
regenerative process initiated by oncogenic B-RAF-driven alveolar disruption provides a tumor-promoting environment
associated with chronic inflammation.
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Introduction
The Ras-mitogen-activated protein kinase (MAPK) pathway is a
key signaling pathway that is involved in the regulation of normal
cell proliferation, survival, growth, differentiation, and apoptosis [1]
[2] [3]. Activating mutations and deregulated expression of the
components of this signaling network are the hallmarks of several
human cancers and other human diseases [1]. To activate the
MAPK signaling cascade, active Ras recruits RAF serine/threonine
kinases to the plasma membrane where they become activated by
several mechanisms [3]. Active RAF then phosphorylates MEK (for
MAPK and extracellular signal-regulated kinase [ERK] kinase),
which subsequently phosphorylates ERK to relay extracellular
stimuli to the nucleus. There are three RAF-family members, A-, B-
and C-RAF. Among these, B-RAF is the most frequently mutated
RAF oncogene in human cancer [4]. Activating B-RAF mutations
were found in melanoma, colorectal, papillary thyroid, ovarian and
non-small-cell lung cancers (NSCLC) [5] [6]. A valine-glutamate
substitution at residue 600 is the most prevalent type of B-RAF
mutation (B-RAF V600E). This mutant exhibits a hyperactive
kinetic function compared to the wild type form and accounts for
,90% of all B-RAF mutations [7].
Deregulation of the mitogenic cascade is found in 50% of lung
cancer patients [8]. Several studies using transgenic mouse models
to understand the link between perturbations of MAPK signaling
and lung cancer were made [9]. These models faithfully mimicked
human NSCLC pathogenesis and predicted alveolar epithelial
type II or Clara cells as the potential cells of origin for neoplastic
transformation [9]. Based on the occurrence of B-RAF V600E
mutations in NSCLC patients, we and others have recently begun
to evaluate the role of this type of B-RAF mutation (B-RAF
V600E) in lung tumor initiation and progression using mouse
models. One of these models employed a knock-in strategy in
which the oncogenic B-RAF allele is activated by infection of lungs
with adenovirus expressing Cre-recombinase [10]. These mice
developed benign neoplastic adenomas in the lung that show some
signs of senescence in the course of disease progression. However,
in this study the tumor-initiating cell could not be identified due to
the promiscuous target cell specificity of the activating virus [10].
In a second study Ji et al. used an inducible rat specific CCSP
promoter that targets both bronchiolar Clara cells as well as a
fraction of type II cells [11] for expression of B-RAF V600E.
However, lung tumor formation in this model was only achieved
in an Ink4A/Arf-/- background [12].
Here we have instead employed the Surfactant Protein C (SpC)
promoter to drive B-RAF V600E expression in type II
pneumocytes. We have previously shown that these cells respond
to C-RAF mediated activation of the mitogenic cascade with
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lesions [12,13]. In contrast to these earlier works, expression of B-
RAF V600E in type II pneumocytes did not readily elicit lung
tumor formation but predominantly resulted in airspace enlarge-
ment accompanied with tissue remodeling and chronic inflamma-
tion. Tumor formation in our transgenic mice was a late event and
displayed low penetrance.
Materials and Methods
Ethics Statement
All animal experiments were performed in accordance with
German legislation on protection of animals and were approved
by the local governmental animal care committee (Regierung-
spraesidium Darmstadt) (permit number V54-19c20/15-B2/233).
Generation of transgenic mice
Mice were housed in air-filtered units with a 12-hour dark/light
circle and with the access to food and water ab libitum. SpC-B-RAF
V600E plasmid was generated by releasing the 2.5 Kb human B-
RAF V600E cDNA from pKS-h B-RAF V600E (unpublished) by
digestion with NotI restriction enzyme and inserted into SPC/
SV40 plasmid (kindly obtained from Jeffrey Whitsett) that was
previously digested with Bam HI endonuclease. Prior to ligation,
both vector and insert were blunt-ended with T4 DNA
polymerase. Correct orientation of the insert was tested by
digestion with XhoI and SalI endonucleases and gel electrophoresis
analysis. SpC-B-RAF V600E expression cassette (6.2 Kb) was
resolved in a low melting agarose gel after digestion with Hind III
restriction enzyme. The purified fragment was then injected into
the pronucleus of fertilized eggs of FVB/n mice. Three positive
founders that showed germ line transmission were obtained. All
founders were backcrossed to C57Bl/6 for more than six
generations before the onset of experiments.
Genotyping
Genotyping of transgenic mice was performed via PCR using
tail lysate as DNA template. To detect the SpC-B-RAF V600E
transgene, SPC-BRAF S1 (59GGA GGA GGT GTG GAA TAT
CAA AC-39) and SPC-BRAF AS1 (59CCA ACA CTT CCA CAT
GCA ATT C-39) primers were used. The PCR conditions applied
were the following: 95uC denaturation for 5 minutes followed by
35 cycles with 95uC denaturation for 30 seconds, 60uC annealing
for 30 seconds and 72uC elongation for 1 minute with a unique
final step at 72uC for 10 minutes. The final PCR product (610 bp)
was resolved in a 1% agarose gel.
Alveolar Type II cells isolation
Alveolar Type II cells were isolated from wild type and SpC-B-
RAF V600E transgenic mice as previously described [14]. Briefly,
lungs were lavaged with 10 ml PBS and tissues were digested with
collagenase/dispase and subsequently minced. The cell suspension
was filtered through 100-, 40- and 10 mm cell strainers and
centrifuged at 130 g for 8 minutes. The cell pellet was resus-
pended in DMEM supplemented with 10% FCS and negative
selection for macrophages/leucocytes was carried out by incuba-
tion on CD45- and CD16/32-precoated Petri dishes for 2 hours at
37uC. The cell suspension was centrifuged at 130 g for 8 minutes
and the cell pellet was snap frozen for further studies.
Reagents and antibodies
For immunohistochemistry, primary antibodies against the
following proteins were used: Aquaporin 5 (AQP-005, Alomone
Labs, 1:1000); BRAF (H-145, Santa Cruz, 1:250); CCSP (sc-9772,
Santa Cruz, 1:2500); CD3 (clone SP7, Lab Vision; 1:1000); CD45
(BD Pharmingen, 1:20); Active Caspase-3 (Asp175) (#9664, Cell
Signaling, 1:200); F4/80 (ab6640, Abcam, 1:100); Ki67 (VPK452,
MM1 Vector laboratories, 1:50); pan-Cytokeratin (Z0622, Dako,
1:500); Pax5 (BD Transduction Laboratories, 1:1000); phospho-
ERK (#4376, Cell Signaling, 1:100); phospho-STAT3 (D3A7,
Cell Signaling, 1:100); Pro SP-C (gift of Jeffrey A. Whitsett); Raf1
(E10, Santa Cruz, 1:100); TTF-1 (M3575, Dako; 1:100); Vimentin
(C-20, Santa Cruz; 1:200). For Western blot analysis antibodies
against the following proteins were used: Active ß-catenin (8E7,
Millipore, 1:2000); BRAF (H-145, Santa Cruz, 1:1000); E-
cadherin (#3195, Cell Signaling, 1:1000); ERK 1/2 (#4695, Cell
Signaling, 1:1000); p120
ctn (6H11, Santa Cruz, 1:1000), phospho-
ERK (#4376, Cell Signaling, 1:1000); phospho-STAT3 (D3A7,
Cell Signaling, 1:2000); Pro-SPC (gift of Jeffrey A. Whitsett); total
STAT3 (124H6, Cell Signaling, 1:1000); ß-catenin (BD Pharmin-
gen, 1:1000); Vimentin (R28, Cell Signaling; 1:1000); ß actin (I10,
Santa Cruz, 1:3000).
RNA isolation and RT-PCR analysis
RNA was isolated from total lung of 16.5 days-old embryos and
adult mice of different ages or from isolated lung type II cells using
Trizol solution (Invitrogen). Isolated type II cells from different
animals were pooled prior to RNA isolation. RNA was treated
with RNase-free-DNase I and cDNA synthesis was performed
using the First-Strand cDNA Synthesis Kit (Fermentas) according
to the manufacturer’s instructions. Control samples were run
without reverse transcriptase in the reaction. To detect SpC-B-
RAF V600E transgene expression, HS-BRAF-S (59-GTC ATC
TTC ATC CTC AGA AG-39) and HM-BRAF-AS (59-TTC AAC
ATT TTC ACT GCC AC-39) primers were used. For the
detection of endogenous murine B-RAF transcript, MM-BRAF-S
(59-CAT CTT CTT CCT CAT CCT CG-39) and HM-BRAF-AS
primers were used. PCR conditions applied were the following:
initial denaturation at 94uC for 5 minutes, followed by a cycle
repeated different number of times with denaturation at 94uC for
30 seconds, annealing at 61uC for 30 seconds and elongation at
72uC for 1 minute followed by a final step at 72u for 5 minutes.
Real time PCR was performed using the DyNAmo
TM HS SYBRH
Green qPCR Kit (Finnzymes) in a Roto- Gene 2000 detection
system (Corbett Research). ß actin or Hypoxanthine-Guanine
Phosphoribosyltransferase (HPRT) were used as standard controls.
Primer sequences are reported in Table S1.
Western blot analysis
Lung tissues were lysed in an ice-cold RIPA buffer (50 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate
[DOC], 1% Nonidet P-40 with protease and phosphatase
inhibitor cocktails) using an Ultra-Turrax homogenizer in a cold
environment. Isolated lung type II cells were lysed in an ice-cold
RIPA buffer by incubating on ice for 20 minutes. After
centrifugation at 11,000 rpm for 10 minutes, supernatants were
transferred into new tubes and protein concentration was
measured using the BCA protein assay kit (Thermo Scientific).
The remaining protein extracts were mixed with 46 laemmli
buffer, heated at 95uC and vortexed for 10 seconds. 30 mg proteins
were resolved by SDS-PAGE and transferred to nitrocellulose
membrane. After 1 h blocking with 5% non-fat-dry-milk in NET-
gelatine (50 mM Tris/HCl pH 7.4, 5 mM EDTA, 0.05% Triton
X-100, 150 mM NaCl, 0,25% gelatine) blots were incubated
overnight at 4uC with primary antibodies, washed three times with
NET-gelatine and incubated for 1 h at room temperature with
peroxidase coupled secondary antibodies (GE Healthcare). After
B-RAF V600E Elicits Lung Malformations
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e29093Figure 1. Induction of alveolar enlargements in mice with targeted expression of mutant B-RAF (V600E) in lung alveolar type II
cells. (A) Schematic representation of the targeting vector. (B) Semi-quantitative RT-PCR shows transgenic- and endogenous- B-RAF expression in
lungs of two wild type and transgenic embryos (E16.5), (cycles=PCR cycle; M=marker; h=human; m=mouse). (C) Paraffin embedded hematoxylin
and eosin (H&E) stained lung sections from mice of different ages show airspace enlargements (arrows) in transgenic animals, (scale bar=100 mm for
the first, second and third panel; 1 mm for the forth panel). (D) Whole lung photographs of 4.5 months old wild type and transgenic mice show a
macroscopic bleb (arrows). (E) Kaplan-Meier survival curve, (log-rank analysis P,0.05; SpC-B-RAF V600E n=59; wild type n=30).
doi:10.1371/journal.pone.0029093.g001
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oped using an ECL kit (Thermo Scientific).
Histopathology and immunostainings
Animals were sacrificed and lungs were fixed under 25 cm
water pressure with 4% buffered paraformaldehyde and
paraffin embedded. 6 mm-cut sections were deparaffinized,
rehydrated in graded series of alcohol and haematoxylin-eosin
stained. For analysis of airspace enlargements lungs from wild
type and transgenic mice were evaluated blindly by two
independent examiners. Tissue samples were graded in the
following manner: 1) Micro- and macro- scopically normal; 2)
Macroscopically normal, but microscopically abnormal [air-
space enlargement]; 3) Macroscopic abnormalities [bulb
formation]. For immunostainings, sections were heated in
10 mM sodium citrate buffer (pH 6) for 10–20 minutes using a
microwave oven. Endogenous peroxidase activity was blocked
by incubation with 1–3% H2O2 in methanol or PBS. Unspecific
binding of the antibodies was prevented by incubation with 3–
5% serum and 0.1% Triton-X in PBS for 1 hour at room
temperature. All primary antibodies were incubated overnight
at 4uC. For phospho-ERK staining, Tris-buffer-saline contain-
ing 0.1% Tween 20 (TBST) was used instead of PBS. For
immune detection of CD45 and F4/80 proteins, antigen
retrieval was done by incubating the lung sections with
20 mg/ml proteinase K in TE buffer (pH 8) for 20 and
7 minutes, respectively. Biotinylated secondary antibodies
(DakoCytomation) were incubated for 90 minutes at a dilution
of 1:200 in blocking solution. ABC reagent was applied
(Vectastain Elite ABX Kit, Vector Labs) and developed in
diaminobenzidine (DAB). Sections were counterstained with
hematoxylin and dehydrated before mounting. For Masson’s
Trichrome staining, the Accustain Trichrome Stain kit (Sigma
Aldrich) was used according to the manufacturer’s instructions.
For Alcian Blue staining, lung sections were deparaffinized,
rehydrated in graded alcohols and incubated in Alcian Blue
(pH 2.5) solution for 30 minutes at room temperature. After
washing in tap water for 5 minutes, sections were counter-
stained with Nuclear Fast Red for 5 minutes, washed with tap
water for 3 minutes, dehydrated and mounted with entellan.
Analysis of mutations
Screening of mutations in tumor samples was carried out as
previously described [15]. The following genes were analyzed for
mutations: EGFR exon 19, 20 21; K-RAS exon 1 and 2; p19
ARF
exon 1; p16
INK4a exon 1; p16
INK4a exon 2; p16
INK4a exon 3; p53
exon 5, 7 and 8; LKB1 exon 1, 2 and 6. Primers that were used are
listed in Table S2.
Figure 2. Immunohistochemical analysis of lung lesions for lung differentiation markers. Paraffin embedded lung sections from wild type
and transgenic mice at 2 months of age were stained for indicated markers; (green arrows point out airspace enlargements), (the red arrow marks the
bronchio-alveolar junction), (red-parenthesis indicates a AQP5 negative sector), (red arrowheads point to Pro-SPC expressing cells), (black arrows
highlight Ki67 positive cells), (Br=bronchiole), (hematoxylin was used as a counterstain), (right panel pictures are high magnification of the red
insets); scale bar=100 mm.
doi:10.1371/journal.pone.0029093.g002
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All statistical analyses were performed using GraphPad Prism4
software. Log-rank analysis was used to compare the survival rate
of different group of mice. Student’s t-test (two-tailed) was used to
compare two groups (P,0.05 was considered significant).
Results
Expression of B-RAF V600E in alveolar type II cells leads
to airspace enlargements in mice
We have generated three transgenic mouse founders for the
expression of B-RAF V600E under the control of the human SpC
promoter (Figure 1A). SpC-B-RAF V600E transgenic mice were
born in the expected mendelian ratios, were fertile and did not
show any gross morphological or behavioral abnormalities.
Analysis of transgene mRNA expression levels among the founders
showed comparable results (Figure S1A). Histopathological
analysis of lung sections from adult mice revealed airspace
enlargements with various degrees in all the founders compared
to control animals (Figure S1B). Interestingly lung tumor
formation was not detected in any of these founders (Figure
S1B). Based on the highest penetrance of the airspace enlarge-
ments, we have selected the founder line number 3 for further
studies. Consistent with the early expression of the transgene
(Figure 1B), we found airspace enlargements in the embryonic
lung sections (Figure 1C) that persisted in both post-natal and
adult lungs of the transgenic animals (Figure 1C). Some of these
alveolar disruptions increased in size over time forming macro-
scopic air-filled structures reminiscent of human bullous-emphy-
sema (Figure 1C–1D and S2A–S2B). The presence of these lesions
affected the life span of animals (Figure 1E). Consistent with the
diminished levels of transgene expression in adult mice (Figure
S3A), neither total B-RAF nor phospho-ERK protein levels
altered between the wild type and transgenic mice (Figure S3B).
Immunohistochemical analysis of cells lining these macroscopic
lesions showed presence of epithelial cell types from the distal lung,
including Clara cells, type I and type II pneumocytes (Figure 2).
Notably, these lesions were often found to be continuous with
bronchio-alveolar junctions (Figure 2). Programmed cell death and
tissue regeneration play an important role during lung morpho-
genesis. We therefore screened lung sections from SpC-B-RAF
V600E transgenic mice of different ages for apoptosis and
proliferation markers. We detected active caspase 3 staining in
lung sections from transgenic mice only at postnatal day 1
(Figure 3A). There was no change in cell proliferation assessed by
Ki67 immunostaining at this age (Figure 3B). However, we found
increased cell proliferation in lungs of transgenic mice at postnatal
day 14 (Figure 3B). Taken together these data suggest that
embryonic expression of B-RAF V600E in alveolar type II cells
impairs lung development leading to airspace enlargements.
Occurrence of tissue remodeling in the lung of SpC-B-
RAF V600E transgenic mice
To further characterize the B-RAF V600E induced lung lesions,
we examined lung sections from wild type and transgenic animals
for the presence of collagen accumulation and mucus secretion
that are the prominent features of chronic lung diseases [16].
Interestingly we detected progressive deposition of collagen
(Figure 4A) in non-epithelial lining sectors of these lesions
(Figure 2, red parenthesis) indicating an ongoing tissue remodel-
ing. In addition to collagen accumulation we also found an age-
related increase in mucus secretion in transgenic mice (Figure 4B).
Epithelial-Mesenchymal-Transition (EMT) was often shown to
be associated with chronic human lung diseases such as COPD
and pulmonary fibrosis [17,18,19,20]. We therefore analyzed total
lung tissue lysates of SpC-B-RAF V600E transgenic mice, which
harbored macroscopic lesions (grade 3) (Figure S2A–S2B) with
Figure 3. Analysis of cell death and cell proliferation in
transgenic mice. (A) Active caspase 3 staining of control and
transgenic animals, (arrows indicate positive cells). (B) Ki67 staining
(brown) of control and transgenic animals. (E=embryonic, P=post-
natal), (hematoxylin was used as a counterstain); scale bar=50 mm.
doi:10.1371/journal.pone.0029093.g003
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cadherin, ß-catenin and increased expression of Vimentin,
indicating EMT induction (Figure 5A), although we cannot rule
out the induction of an alveolar maintenance program in alveolar
type II cells [21]. Expression of Vimentin was not solely localized
next to the lesions but also abundantly found in fibrotic lung
parenchyma (Figure 5B). Since the transgenic lungs show airspace
enlargements and inflammation, these results could simply reflect
the relative changes in cell populations in the lung rather than an
EMT phenomenon. We therefore analyzed the same markers in
isolated alveolar type II cells from mice that in this case did not
show macroscopic lesions by Real-Time PCR and immunoblot-
ting. We found significantly reduced E-cadherin and increased
Vimentin mRNA levels in isolated type II cells from SpC-B-RAF
V600E mice (Figure 5C). Different from the mRNA data, we
detected equal to mildly decreased levels of E-cadherin in protein
lysates from transgenic animals (Figure 5D). In contrast, variable
levels of Vimentin expression were detected between the samples
(Figure 5D). As in the case of the total lung lysates we observed
strongly reduced levels of ß-catenin in type II cells from mutant
mice (Figure 5A and 5D). In addition to ß-catenin, the levels of
p120
ctn were also reduced (Figure 5D). ß-catenin is a key signaling
mediator of the canonical WNT signaling [22]. Interestingly, in
both total lung and isolated type II cells protein lysates from SpC-
B-RAF V600E mice we detected diminished levels of active ß-
catenin expression suggesting an inhibition of the canonical WNT
signaling pathway (Figure 5A and 5D).
Induction of inflammation in SpC-B-RAF V600E
transgenic mice
Chronic inflammation is a prominent feature of degenerative
lung diseases in human [23]. To assess the involvement of immune
Figure 4. Collagen accumulation and Goblet cells hyperplasia in aged SpC-B-RAF V600E transgenic mice. (A) Masson’s Trichrome
staining shows collagen (blue), red-parenthesis indicates Masson’s Trichrome negative parts, (the right panel pictures are high magnification of the
red insets). (B) Representative pictures of Alcian blue stained paraffin embedded lung sections from wild type and transgenic mice at 3 and 12
months of age, respectively, black arrowheads denote Alcian Blue-positive (blue) regions indicative of increased mucus production; scale
bar=100 mm.
doi:10.1371/journal.pone.0029093.g004
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lung sections from young (1–3 months) and aged (4–28 months)
miceusingdifferentimmunecell markers.Progressiveaccumulation
ofinfiltratingmacrophageswasobservedinthevicinityofthe lesions
(Figure 6). In some cases, this massive accumulation led to
granulomas formation in transgenic mice (Figure 6). Interestingly
mast cells were detected in the walls lining the enlarged air spaces
(Figure 7A). Moreover, we found lymphoid follicles consisting of T-
and B-cells in lungs of SpC-B-RAF V600E transgenic mice
(Figure 7B and Figure S4). In extreme cases, these lymphoid
aggregates reached very large sizes occupying most of the air
exchange spaces of the entire lung (Figure S5A). These CD45
positive clusters were surrounded by intense collagen accumulations
(Figure S5B). In order to evaluate the potential role of the adaptive
immunity in the development of the B-RAF V600E-induced lung
lesions, SpC-B-RAF V600E single transgenic mice were crossed
with RAG1-null mice that lack mature T- and B- lymphocytes [24].
Histological examination of lung sections from compound mice
(SpC-B-RAF V600E/RAG1 KO) demonstrated the persistence of
these lesions indicating that T- and B- cells are not involved in the
lung pathogenesis in our system (Figure S6A and S6B). In order to
identify the mechanisms by which B-RAF V600E triggers
inflammation, IL-6/signal transducer and activator of transcription
3 (STAT3),a wellknown inducerofinflammation [25],was studied.
Western blot analysis of lung protein lysates showed up-regulation
of phospho-STAT3 in transgenic animals (Figure 8A). Immuno-
staining of lung sections with phospho-STAT3 specific antibody
showed similar results indicating the activation of STAT3 signaling
in SpC-B-RAF V600E mice (Figure 8B).
Delayed tumor formation in SpC-B-RAF V600E transgenic
mice
As there is a large body of clinical evidence that human chronic
lung diseases may be linked with the late onset lung cancer [26]
Figure 5. Analysis of Epithelial-Mesenchymal-Transition (EMT) in SpC-B-RAF V600E transgenic mice. (A) Total lung protein lysates from
two wild type (wt) and transgenic (tg) littermates (17 and 21 months old) were gel separated and immunoblotted with the indicated antibodies. (B)
Immunostaining of lung sections from wild type and SpC-B-RAF V600E transgenic mice for Vimentin (brown), (E=airspace enlargement), hematoxylin
was used as a counterstain, scale bar=100 mm. (C) Analysis of E-cadherin and Vimentin mRNA levels in alveolar type II cells isolated from wild type
and SpC-B-RAF V600E transgenic mice (5 months old) by Real time PCR, data represent mean+SEM, (t-test *=P,0,05, **=P,0,01, n=3–4). (D)
Protein lysates of isolated type II cells from two wild type (wt) and transgenic (tg) littermates (20 months old) were gel separated and immunoblotted
with the indicated antibodies.
doi:10.1371/journal.pone.0029093.g005
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In comparison to wild type control littermates, we detected single
focal lung tumors with low incidence (10%) in SpC-B-RAF V600E
transgenic mice (Figure 9A and 9B). Notably, tumors were always
found in lungs with airspace enlargements (Figure 9B). Lung
tumors stained positive for TTF-1, Pro-SPC, and Aquaporin-5
and negative for CCSP indicating a type II pneumocyte origin
(Figure 9C). Immunohistochemical analysis of tumors with the
components of mitogenic cascade signaling showed positive
staining for both B-RAF and phospho-ERK1/2 but not for C-
RAF (Figure 9C). Low incidence and late latency of lung tumors
from SpC-B-RAF V600E mice are in the favor of a spontaneous
origin. We therefore screened tumor samples for somatic
mutations that are commonly found in human and mouse
NSCLC [4]. Interestingly the majority of the tumors were
negative for these mutations (Figure S7).
Discussion
Mutations in the components of the mitogenic cascade play an
important role in both developmental syndromes and neoplastic
diseases [28]. Individuals with these syndromes often have
mutations in this signaling pathway that predisposes them to cancer
too [28]. NSCLC is the leading cause of cancer related death
worldwide and frequently harbors activating mutations in the
MAPK pathway [8]. A fraction (,2%) of NSCLC patients harbors
B-RAF mutations [4] and several studies earlier attempted to model
human NSCLC in mice. They have shown that conditional
expression of B-RAF V600E rapidly induces lung adenoma
formation [10,12]. However, in our study, constitutive expression
of this mutant B-RAF in type II pneumocytes did not elicit
immediate tumor formation but predominantly caused airspace
enlargements which were often associated with inflammation. Lack
of tumor formation in SpC-B-RAF V600E transgenic mice in
comparison to the SpC-C-RAF BxB mice [13] is intriguing, as both
oncogenes are known to activate the mitogenic cascade. It is
plausible that the diminished transgene expression caused by the
induction of apoptosis during lung development precluded
oncogenic transformation of alveolar type II cells. The absence of
elevated phospho-ERK levels in transgenic mice supports such a
hypothesis. Alternatively, as reported previously, induction of
cellular senescence program by oncogenic B-RAF may restrict
expansion of transformed cells [29]. However, we did not find
detectable levels of p16
INK4a, p21
WAF1 and p19
ARF, the common
Figure 6. Progressive accumulation of macrophages in the lung
of SpC-B-RAF V600E transgenic mice. Paraffin embedded lung
sections from mice with the indicated genotypes and ages stained for
F4/80 (brown), E=airspace enlargement, arrowheads show diffused
alveolar macrophages, hematoxylin was used as a counterstain, scale
bar=100 mm.
doi:10.1371/journal.pone.0029093.g006
Figure 7. Infiltration of immune cells in B-RAF V600E-induced
lung lesions. (A) Toluidine blue staining identifies mast cells (purple)
in the epithelial lining of a lesion. (B) Staining of paraffin embedded
lung sections from wild type and transgenic mice for CD45 (brown),
hematoxylin was used as counterstain, the right panel pictures are high
magnification of the red insets; scale bar=100 mm.
doi:10.1371/journal.pone.0029093.g007
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by immunoblotting nor by immunohistochemistry in transgenic
mice from different ages (data not shown).
In the present study, the expression of B-RAF V600E
specifically in alveolar type II cells during lung development
affected alveolar formation. Earlier studies showed that the
canonical WNT signaling plays a crucial role during lung
development [22]. Inhibition of WNT signaling by conditional
knockout of ß-catenin in alveolar type II cells disrupted lung
morphogenesis and caused respiratory failure due to dilated
terminal structures in their lungs [22]. The airspace enlargements
that we find in our transgenic mice may be related to the
downregulation of WNT signaling that we detected in isolated
type II pneumocytes. Interestingly, similar to oncogenic B-RAF,
activation of oncogenic K-ras
G12D, the most frequent mutation
found in human NSCLC, was shown to impair lung morphogen-
esis by up-regulating Ras/MAPK antagonist Sprouty-2 in the
absence of apoptosis [30]. It remains to be elucidated whether
Sprouty-2 or other antagonists of the mitogenic cascade play a role
in generation of developmental defects induced by B-RAF V600E
in our transgenic model.
The airspace enlargements observed in embryonic lungs of
SpC-B-RAF V600E transgenic mice were maintained in adult
animals and were associated with tissue remodeling and chronic
inflammation. Accumulations of collagen and mucus secretion that
we found in transgenic lungs suggest that there is an ongoing tissue
repair. However, persistence of the airspace enlargements
throughout the lifetime of the animals indicates that there is an
inefficient recovery of the lung epithelium. Inhibition of canonical
WNT signaling as well as absence of full EMT in lungs of
transgenic animals may account for incomplete repair. Chronic
inflammation plays also an important role in tissue remodeling by
promoting the release of cytokines by immune cells [31]. STAT3,
a cytokine-induced gene related to pulmonary inflammation in
human COPD, has been shown to be required for alveolar
structure maintenance and function [32]. Persistent activation of
the STAT3 signaling in murine respiratory epithelial cells was also
shown to induce pulmonary inflammation and tumor formation in
the lung [32]. Moreover STAT3 is a potent mediator of pro-
inflammatory interleukin 6 (IL-6) that was shown to induce EMT
phenotype in human breast cancer cells [33]. Abundant expression
of activated STAT3 that we found in lungs of SpC-B-RAF V600E
transgenic mice may indicate a role for STAT3 in the promotion
of tissue remodeling and inflammation in our system.
Histopathological analysis of the infiltrating immune cells
present in SpC-B-RAF V600E transgenic mice demonstrated the
Figure 8. Activation of STAT3 signaling in SpC-B-RAF V600E transgenic mice. (A) Total lung protein lysates from two wild type (wt) and
transgenic (tg) littermates (17 and 21 months old) were gel separated and immunoblotted with the indicated antibodies. (B) Phospho-STAT3
immunostaining of lung sections shows accumulation of STAT3 positive cells in transgenic mice (arrows indicate a macroscopic bleb, arrowheads
point to Phospho-STAT3 positive cells), the right panel pictures are high magnification of the red insets, hematoxylin was used as a counterstain, scale
bar=1 mm in the right and 100 mm in the left panel pictures.
doi:10.1371/journal.pone.0029093.g008
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immune system. The presence of lymphoid aggregates consisting
of T- and B-cells raises the question whether there was a specific
immune response to B-RAF V600E. We have previously
described a T-cell specific epitope of B-RAF V600E [34] that
could be involved in immune selection, suggesting that the
immune response might be the driving force behind the
development of these lesions in the transgenic animals. However,
Figure 9. Lung tumor formation in SpC-B-RAF V600E transgenic mice. (A) Tumor incidence as a function of age, log-rank analysis for wild
type (n=59) and SpC-B-RAF V600E (n=102) transgenic mice, P,0.05. (B) H&E staining of lung section from a one year old SpC-B-RAF V600E
transgenic mouse shows coexistence of the lung lesions (arrowheads) with a lung tumor (arrow); scale bar=500 mm. (C) Tumor bearing lung sections
were stained with the indicated markers, hematoxylin was used as counterstain; scale bar=100 mm.
doi:10.1371/journal.pone.0029093.g009
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PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e29093lack of immune cells in embryonic lungs with airspace
enlargements and persistence of these lesions in lungs from
SpC-B-RAF V600E/RAG1-null compound mice suggest that
cells of the adaptive immune system are dispensable in the course
of the disease. In fact, cells from the innate immune system; such
as macrophages and mast cells were abundantly found in the
lungs of transgenic animals. The progressive accumulation of
macrophages as well as lymphoid aggregates might contribute to
an elevated mucus production and increased damage observed in
these lesions. In addition to macrophages, mast cells have
important roles in innate immunity and tissue remodeling but
were poorly studied in human COPD [35]. Our data suggest that
mast cells might play a role in the progression of chronic lung
degeneration and therefore should be examined in more detail in
future.
It has been previously shown that the expression of B-RAF
V600E in lung epithelial cells induced lung tumor formation. In
contrast to these previous studies, we found that the early
expression of mutant B-RAF in alveolar type II cells caused
airspace enlargements in the absence of lung tumors. The
differences between these models might result from a different
targeting strategy, as well as different timing of oncogene
induction [10] [12]. Nevertheless we detected lung tumors with
low incidence only in aged transgenic animals. The presence of
single focal tumors with low penetrance in transgenic mice
suggests a spontaneous origin. However, the rate of spontaneous
tumor formation in transgenic mice was significantly higher than
in C57BL/6 mice [36]. Consistent with the link between
inflammation and cancer, the increased number of spontaneous
lung tumors found in SpC-B-RAF V600E mice might be due to
inflammation that was often associated with the airspace
enlargements.
Supporting Information
Figure S1 Comparable formation of airspace enlarge-
ments in different SpC-B-RAF V600E transgenic founder
lines. (A) Analysis of B-RAF V600E mRNA levels between the
founders (2 weeks old) by Real-Time PCR, data represent
mean+SEM, (t-test ns=not significant, n=3). (B) Representative
paraffin embedded H&E stained lung sections from wild type and
transgenic mice (2 months old), right panel pictures are the high
magnification of red insets, scale bar=100 mm.
(TIF)
Figure S2 Scoring of B-RAF V600E induced lung lesions
in transgenic mice. (A) Representative pictures of H&E
stained lung sections from wild type and transgenic mice show
airspace enlargements with different grades. The scoring was
performed as follow: 1) Micro- and macro-scopically normal; 2)
Macroscopically normal, but microscopically abnormal [airspace
enlargement]; 3) Macroscopic abnormalities [bulb formation,
pointed by arrows]. Scale bar=1 mm for low magn. and 100 mm
for high magn. pictures. (B) Incidence of the lung lesions with
different grades, (n=59 for wild type, n=102 for SpC-B-RAF
V600E).
(TIF)
Figure S3 Diminished transgene expression and lack of
phospho-ERK upregulation in SpC-B-RAF V600E mice.
(A) Semi quantitative RT-PCR analysis of total lung RNA samples
from wild type (wt) and transgenic (tg) animals shows different
levels of transgene expression between embryonic and adult mice,
HPRT was used as an internal control. (B) Total lung protein
lysates from two wild type (wt) and transgenic (tg) littermates were
gel separated and immunoblotted; ages and antibodies are as
indicated.
(TIF)
Figure S4 Presence of T- and B- cells in CD45 positive
clusters. Lung sections from SpC-B-RAF V600E transgenic
mice were stained for CD3 and PAX5 to identify T- and B- cells,
respectively; hematoxylin was used as a counterstain; scale
bar=100 mm.
(TIF)
Figure S5 Severe lung degeneration in an aged (17.5
months) mouse transgenic for B-RAF V600E. (A) H&E
staining of a lung section shows massive infiltration of leukocytes
(red arrows). (B) Masson’s Trichrome staining of the consecutive
lung section reveals collagen-enriched regions (blue), the right
panel are high magnifications of the yellow inserts; scale
bar=1 mm for the left and 100 mm for the right panel.
(TIF)
Figure S6 Mature T- and B- cells are dispensable for the
formation of SpC-B-RAF V600E-induced lung lesions. (A)
H&E staining of lung sections from wild type, RAG1 knock out
(KO), SpC-B-RAF V600E single transgenic and SpC-B-RAF
V600E/RAG1 KO compound animals show the persistence of
airspace enlargements in SpC-B-RAF V600E single and com-
pound mice, green arrows point to airspace enlargements. (B)
Immunostaining of paraffin embedded lung sections from RAG1
KO single transgenic and SpC-B-RAF V600E/RAG1 KO
compound animals for CD45 (brown), red arrows point to
CD45 positive clusters, hematoxylin was used as a counterstain;
scale bar=100 mm.
(TIF)
Figure S7 Lung tumors found in SpC-B-RAF V600E
transgenic mice in general do not harbor mutations
frequently present in human and mouse NSCLC.
Genomic DNA from lung tumors of SpC-B-RAF V600E
transgenic mice were screened for the indicated genes, individual
animal (ID) and Exon numbers are as indicated, wt=wild type,
Hetero=heterozygous, Homo=homozygous, empty boxes repre-
sent untested samples.
(TIF)
Table S1 Primers for Real time PCR.
(DOCX)
Table S2 Primers for the amplification of genomic
DNA.
(DOCX)
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